Which COVID-19 vaccine should I get?

Should I try and get an mRNA vaccine? They are better than the others, aren’t they? If I show up at the clinic can I choose?

 These are some of the questions that we didn’t even know we would be so lucky to ask just three months ago. 

The speed at which multiple vaccines to choose from has come about is unprecedented. 

The first genome sequence of a previously unknown virus was published in early January 2020 and the Pfizer and Moderna mRNA vaccines, tested over the summer and fall of 2020, were approved for emergency use in early December. 

These are the quickest vaccines ever developed. Their very speed has raised a lot of questions around their safety. It is true that all previous vaccines have taken years to develop and the cumulative experience of their use over time is reassuring. 

Moderate reactions

Nevertheless the COVID-19 vaccines have been tested in very big trials. As a comparison, the widely used and “uncontroversial” Shingrix vaccine for prevention of shingles was tested in 32,000 participants prior to submission for approval in 2017. The total number of patients in COVID-19 vaccine trials that have reported results so far is 170,000 and growing rapidly. 

The safety results have been reassuring — both in the trial participants and now in millions of people worldwide who have been vaccinated and reported to national monitoring systems. 

Rates of severe side effects, mainly anaphylaxis, have been very rare — a handful in every million vaccinated — and the more common reactions such as arm pain, fever, fatigue and muscle aches have been over very quickly. 

The brief discomfort of COVID-19 vaccines seems to be greater than for the annual flu shot. This probably reflects a combination of both the “prime-boost” two-shot strategy to provoke maximum stimulation of the immune system; and the large group of vaccinees who were recently infected naturally with SARS-CoV-2 and already have a naturally primed immune system ready to react. Maybe the single-shot Johnson & Johnson vaccine will have fewer reactions?

Don’t compare the numbers

There are now three vaccines available in the USA (Pfizer, Moderna and Johnson & Johnson) and several more globally, with more to come. 

Inevitable comparisons between the different vaccines, using their “headline” efficacy numbers, is a favorite media story at the moment. This has stimulated “vaccine shopping,” which has reached damaging levels in places like Germany, where the UK Astra-Zeneca vaccine sits un-used in warehouses whilst people wait, unprotected, for the Pfizer vaccine. 

The efficacy numbers attached to the two shots is responsible for this: 95% for Pfizer versus 62% for Astra-Zeneca. 

These numbers are a snapshot in time and can’t be compared with each other. 

Different vaccine trials

The Pfizer number was generated from a trial mainly in the USA, where most of the patients were recruited in the summer and fall of 2020. 

The Astra-Zeneca number was reported from a trial that included a substantial mixture of patients from the UK, South Africa and Brazil. 

The Pfizer and Moderna trials closely adhered to the three- or four-week interval between doses, whereas the Astra-Zeneca trial had a less strict timing. 

The different trials measured infection and symptoms in different ways at different time points. 

In more recent trials — for example the Johnson & Johnson and Novavax trials — there were large numbers of infections with new virus variants included as well. 

The efficacy result of each trial is reflective of the performance of the vaccine WITHIN that trial compared with a placebo — but not comparable OUTSIDE of the trial with the other vaccines.

Real-world results

To emphasize this, we have recent large-scale program results from the Scottish National Health Service. 

The Astra-Zeneca vaccine has been 94% effective in reducing hospitalizations so far compared with the Pfizer vaccine, which has been 85% effective. 

This reversal of efficacy rankings in a real-world observation simply emphasizes that both vaccines are great. 

The most important number of all to remember is that in the thousands and thousands of trial participants who received any of the vaccines there were no COVID deaths and almost no hospitalizations for COVID.

So when you have finally managed to find your vaccine appointment after refreshing the sign-up page a hundred times and been booked four weeks hence, don’t worry about which vaccine you will get. Just pick the one with the smallest needle.

 

James Shepherd, MD PhD, lives in Sharon and is an Infectious Disease physician and epidemiologist who is on the faculty of the Yale University School of Medicine.

Latest News

Wake Robin Inn sold after nearly two years of land-use battles

The Wake Robin Inn in Lakeville has been sold for $3.5 million following nearly two years of land-use disputes and litigation over its proposed redevelopment.

Photo courtesy of Houlihan Lawrence Commercial Real Estate

LAKEVILLE — The Wake Robin Inn, the historic country property at the center of a contentious land-use battle for nearly two years, has been sold for $3.5 million.

The 11.52-acre hilltop property was purchased by Aradev LLC, a hospitality investment firm planning a major redevelopment of the 15,800-square-foot inn. The sale was announced Friday by Houlihan Lawrence Commercial, which represented the seller, Wake Robin LLC.

Keep ReadingShow less
Kent commission tackles Lane Street zoning snag
Lane Street warehouse conversion raises zoning concerns in Kent
By Alec Linden

KENT — The Planning and Zoning Commission is working to untangle a long-standing zoning complication affecting John and Diane Degnan’s Lane Street property as the couple seeks approval to convert an old warehouse into a residence and establish a four-unit rental building at the front of the site.

During the commission’s Feb. 12 meeting, Planning and Zoning attorney Michael Ziska described the situation as a “quagmire,” tracing the issue to a variance granted by the Zoning Board of Appeals roughly 45 years ago that has complicated the property’s use ever since.

Keep ReadingShow less
Kent P&Z closes High Watch hearing, continues deliberations

Kent Town Hall, where the Planning and Zoning Commission closed a public hearing on High Watch Recovery Center’s permit modification request on Feb. 12

Leila Hawken

KENT — The Planning and Zoning Commission on Feb. 12 closed a long-running public hearing on High Watch Recovery Center’s application to modify its special permit and will continue deliberations at its March meeting.

The application seeks to amend several conditions attached to the addiction treatment facility’s original 2019 permit. High Watch CEO Andrew Roberts, who first presented the proposal to P&Z in November, said the changes are intended to address issues stemming from what he described during last week's hearing as “clumsily written conditions.”

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Kent committee to review Swift House options

The Swift House in Kent has been closed to the public since the COVID-19 pandemic. A newly appointed town committee will review renovation costs and future options for the historic property.

Alec Linden

KENT — Town officials have formed a seven-member committee to determine the future of the shuttered, town-owned Swift House, launching what could become a pivotal decision about whether Kent should invest in the historic property — or divest from it altogether.

The Board of Selectmen made the appointments on Wednesday, Feb. 11, following recent budget discussions in which the building’s costs and long-term viability were raised.

Keep ReadingShow less

Kathleen Rosier

Kathleen Rosier

CANAAN — Kathleen Rosier, 92, of Ashley Falls Massachusetts, passed away peacefully with her children at her bedside on Feb. 5, at Fairview Commons Nursing Home in Great Barrington, Massachusetts.

Kathleen was born on Oct. 31,1933, in East Canaan to Carlton and Carrie Nott.

Keep ReadingShow less

Carolyn G. McCarthy

Carolyn G. McCarthy

LAKEVILLE — Carolyn G. McCarthy, 88, a long time resident of Indian Mountain Road, passed away peacefully at home on Feb. 7, 2026.

She was born on Sept. 8, 1937, in Hollis, New York. She was the youngest daughter of the late William James and Ruth Anderson Gedge of Indian Mountain Road.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.